Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

BACKGROUND: Rotigotine is a unique dopamine agonist with activity across D1 through D5 receptors as well as select adrenergic and serotonergic sites. This study reports the 2-year follow-up safety and efficacy data of an ongoing open-label multicenter extension study (NCT00498186) of transdermal rot...

Descripción completa

Detalles Bibliográficos
Autores principales: Högl, Birgit, Oertel, Wolfgang H, Stiasny-Kolster, Karin, Geisler, Peter, Beneš, Heike, García-Borreguero, Diego, Trenkwalder, Claudia, Poewe, Werner, Schollmayer, Erwin, Kohnen, Ralf
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958158/
https://www.ncbi.nlm.nih.gov/pubmed/20920156
http://dx.doi.org/10.1186/1471-2377-10-86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958158/
https://www.ncbi.nlm.nih.gov/pubmed/20920156
http://dx.doi.org/10.1186/1471-2377-10-86

Ejemplares similares